Rhesus Macaque CODEX Multiplexed Immunohistochemistry Panel for Studying Immune Responses During Ebola Infection.
EBOV (Ebola virus)
NHP (non-human primate)
Spatial biology
codex
multiplexed immunofluorescencence and immunohistochemistry
rhesus macaque (Macaca mulatta tcheliensis)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
06
2021
accepted:
16
11
2021
entrez:
23
12
2021
pubmed:
24
12
2021
medline:
11
2
2022
Statut:
epublish
Résumé
Non-human primate (NHP) animal models are an integral part of the drug research and development process. For some biothreat pathogens, animal model challenge studies may offer the only possibility to evaluate medical countermeasure efficacy. A thorough understanding of host immune responses in such NHP models is therefore vital. However, applying antibody-based immune characterization techniques to NHP models requires extensive reagent development for species compatibility. In the case of studies involving high consequence pathogens, further optimization for use of inactivated samples may be required. Here, we describe the first optimized CO-Detection by indEXing (CODEX) multiplexed tissue imaging antibody panel for deep profiling of spatially resolved single-cell immune responses in rhesus macaques. This 21-marker panel is composed of a set of 18 antibodies that stratify major immune cell types along with a set three Ebola virus (EBOV)-specific antibodies. We validated these two sets of markers using immunohistochemistry and CODEX in fully inactivated Formalin-Fixed Paraffin-Embedded (FFPE) tissues from mock and EBOV challenged macaques respectively and provide an efficient framework for orthogonal validation of multiple antibody clones using CODEX multiplexed tissue imaging. We also provide the antibody clones and oligonucleotide tag sequences as a valuable resource for other researchers to recreate this reagent set for future studies of tissue immune responses to EBOV infection and other diseases.
Identifiants
pubmed: 34938283
doi: 10.3389/fimmu.2021.729845
pmc: PMC8685521
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
729845Subventions
Organisme : NIAID NIH HHS
ID : HHSN272200700016I
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201800013C
Pays : United States
Organisme : NIH HHS
ID : P51 OD011107
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA196585
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007290
Pays : United States
Informations de copyright
Copyright © 2021 Jiang, Mukherjee, Bennett, Chen, Logue, Dighero-Kemp, Kurtz, Adams, Phillips, Schürch, Goltsev, Hickey, McCaffrey, Delmastro, Chu, Reader, Keesler, Galván, Zlobec, Van Rompay, Liu, Hensley, Nolan and McIlwain.
Déclaration de conflit d'intérêts
GN and YG are co-founders and stockholders of Akoya Biosciences, Inc. GN, YG, and DM are inventors on CODEX-related patents US9909167 and US9909167B2, respectively. CS is a scientific advisor to Enable Medicine, Inc. CS, DP, and GN are inventors on a patent application related to CODEX (PCT/US2021/016641). EFM has previously consulted for Ionpath, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Elife. 2018 Jul 11;7:
pubmed: 29993362
Front Immunol. 2021 May 19;12:687673
pubmed: 34093591
Proc Natl Acad Sci U S A. 2020 Dec 29;117(52):33455-33465
pubmed: 33376221
Nat Methods. 2014 Apr;11(4):417-22
pubmed: 24584193
Cell. 2018 Aug 9;174(4):968-981.e15
pubmed: 30078711
Cell. 2020 Nov 25;183(5):1383-1401.e19
pubmed: 33159858
Am J Pathol. 2020 Sep;190(9):1867-1880
pubmed: 32479821
Eur J Immunol. 2021 May;51(5):1262-1277
pubmed: 33548142
Nat Commun. 2021 Nov 18;12(1):6726
pubmed: 34795254
Nat Rev Immunol. 2018 Jun;18(6):390-404
pubmed: 29556017
Nat Methods. 2016 Oct;13(10):823-7
pubmed: 27595404
Sci Rep. 2018 Jan 19;8(1):1250
pubmed: 29352230
J Med Primatol. 2016 Jun;45(3):139-46
pubmed: 27221549
Viruses. 2020 Jul 14;12(7):
pubmed: 32674252
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Nat Med. 2014 Apr;20(4):436-42
pubmed: 24584119
Cell. 2020 Jul 23;182(2):497-514.e22
pubmed: 32579974
Nat Rev Dis Primers. 2020 Feb 20;6(1):13
pubmed: 32080199
J Histochem Cytochem. 2011 Apr;59(4):356-65
pubmed: 21411807
J Histochem Cytochem. 2009 Dec;57(12):1159-67
pubmed: 19729671
Expert Opin Drug Saf. 2018 Oct;17(10):971-973
pubmed: 30198799
Clin Vaccine Immunol. 2014 Dec;21(12):1605-12
pubmed: 25230936
Cell. 2020 Sep 3;182(5):1341-1359.e19
pubmed: 32763154
Cell. 2018 Sep 6;174(6):1373-1387.e19
pubmed: 30193111